indication_id,agency,description,indication,cancer_type,approval_url,publication_date,therapy_name,therapy_approach,therapy_strategy,therapy_type,biomarker
ind:hc.adcetris:0,hc,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.","ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Anaplastic Large Cell Lymphoma,https://pdf.hres.ca/dpd_pm/00080158.PDF,2025-04-08,"['Cyclophosphamide', 'Brentuximab Vedotin', 'Prednisone', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'target CD30 antigens', 'Corticosteroid', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['CD30 + [present]']
ind:hc.adcetris:0,hc,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.","ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Angioimmunoblastic T-Cell Lymphoma,https://pdf.hres.ca/dpd_pm/00080158.PDF,2025-04-08,"['Cyclophosphamide', 'Brentuximab Vedotin', 'Prednisone', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'target CD30 antigens', 'Corticosteroid', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['CD30 + [present]']
ind:hc.adcetris:0,hc,"Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.","ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).","Peripheral T-Cell lymphoma, NOS",https://pdf.hres.ca/dpd_pm/00080158.PDF,2025-04-08,"['Cyclophosphamide', 'Brentuximab Vedotin', 'Prednisone', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'target CD30 antigens', 'Corticosteroid', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['CD30 + [present]']
ind:hc.adcetris:1,hc,Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.,ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy,Mycosis Fungoides,https://pdf.hres.ca/dpd_pm/00080158.PDF,2025-04-08,"['Cyclophosphamide', 'Brentuximab Vedotin', 'Prednisone', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'target CD30 antigens', 'Corticosteroid', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['CD30 + [present]']
ind:hc.afinitor:0,hc,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00063824.PDF,2021-11-30,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hc.afinitor:0,hc,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00063824.PDF,2021-11-30,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hc.afinitor:0,hc,"Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.","AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00063824.PDF,2021-11-30,"['Everolimus', 'Exemestane']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Aromatase inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hc.alecensaro:0,hc,"Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.","ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078825.PDF,2025-03-11,['Alectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.alunbrig:0,hc,"Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.",ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00066731.PDF,2022-07-19,['Brigatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.augtyro:0,hc,Health Canada approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080483.PDF,2025-05-07,['Repotrectinib'],Monotherapy,['ROS inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:hc.balversa:0,hc,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.","BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",Bladder Urothelial Carcinoma,https://pdf.hres.ca/dpd_pm/00077812.PDF,2024-11-20,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.R248C [present]']
ind:hc.balversa:0,hc,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.","BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",Bladder Urothelial Carcinoma,https://pdf.hres.ca/dpd_pm/00077812.PDF,2024-11-20,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.S249C [present]']
ind:hc.balversa:0,hc,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.","BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",Bladder Urothelial Carcinoma,https://pdf.hres.ca/dpd_pm/00077812.PDF,2024-11-20,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.G370C [present]']
ind:hc.balversa:0,hc,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.","BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",Bladder Urothelial Carcinoma,https://pdf.hres.ca/dpd_pm/00077812.PDF,2024-11-20,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3 p.Y373C [present]']
ind:hc.balversa:0,hc,"Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.","BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.",Bladder Urothelial Carcinoma,https://pdf.hres.ca/dpd_pm/00077812.PDF,2024-11-20,['Erdafitinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR3::TACC3 [present]']
ind:hc.besponsa:0,hc,Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00077730.PDF,2024-11-08,['Inotuzumab ozogamicin'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['CD22 + [present]']
ind:hc.blincyto:2,hc,Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00078156.PDF,2024-12-27,['Blinatumomab'],Monotherapy,['CD19 inhibition'],['Immunotherapy'],['CD19 + [present]']
ind:hc.bosulif:0,hc,Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).,BOSULIF (bosutinib) is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).,Chronic Myelogenous Leukemia,https://pdf.hres.ca/dpd_pm/00076285.PDF,2024-07-12,['Bosutinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.bosulif:1,hc,"Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.","BOSULIF (bosutinib) is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.",Chronic Myelogenous Leukemia,https://pdf.hres.ca/dpd_pm/00076285.PDF,2024-07-12,['Bosutinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.braftovi:0,hc,"Health Canada approved encorafenib in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.","BRAFTOVI (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",Melanoma,https://pdf.hres.ca/dpd_pm/00074711.PDF,2024-02-23,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.braftovi:1,hc,"Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.","BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.",Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00074711.PDF,2024-02-23,"['Cetuximab', 'Encorafenib']",Combination Therapy,"['EGFR inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.cotellic:0,hc,Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://pdf.hres.ca/dpd_pm/00070061.PDF,2023-03-24,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.cotellic:0,hc,Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.,Melanoma,https://pdf.hres.ca/dpd_pm/00070061.PDF,2023-03-24,"['Cobimetinib', 'Vemurafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hc.enhertu:0,hc,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.","ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078361.PDF,2025-01-17,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.enhertu:1,hc,Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).,ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).,Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078361.PDF,2025-01-17,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.enhertu:0,hc,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.","ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078361.PDF,2025-01-17,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-low [present]']
ind:hc.enhertu:3,hc,"Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable,locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.","ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.",Adenocarcinoma of the Gastroesophageal Junction,https://pdf.hres.ca/dpd_pm/00078361.PDF,2025-01-17,['Trastuzumab deruxtecan'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.erbitux:0,hc,"Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.","ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.",Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00043071.PDF,2018-01-10,"['Fluorouracil', 'Irinotecan', 'Cetuximab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']","['EGFR positive [present]', 'Wild type KRAS [present]']"
ind:hc.erbitux:1,hc,Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.,ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.,Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00043071.PDF,2018-01-10,"['Irinotecan', 'Cetuximab']",Combination Therapy,"['Topoisomerase I inhibition', 'EGFR inhibition']","['Chemotherapy', 'Targeted therapy']","['EGFR positive [present]', 'Wild type KRAS [present]']"
ind:hc.erbitux:2,hc,Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who are intolerant to irinotecan-based chemotherapy.,ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).,Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00043071.PDF,2018-01-10,['Cetuximab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['EGFR positive [present]', 'Wild type KRAS [present]']"
ind:hc.erbitux:3,hc,Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.,ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.,Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00043071.PDF,2018-01-10,['Cetuximab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['EGFR positive [present]', 'Wild type KRAS [present]']"
ind:hc.faslodex:0,hc,"Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.","FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00053975.PDF,2019-11-15,['Fulvestrant'],Monotherapy,['Estrogen receptor inhibition'],['Hormone therapy'],"['ER positive [present]', 'HER2-negative [present]']"
ind:hc.giotrif:0,hc,Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00051644.PDF,2019-06-06,['Afatinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR somatic variants [present]']
ind:hc.giotrif:0,hc,Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00051644.PDF,2019-06-06,['Afatinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hc.gleevec:0,hc,"Health Canada approved imatinib mesylate for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.","GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.",Chronic Myelogenous Leukemia,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.gleevec:1,hc,"Health Canada approved imatinib mesylate for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.","GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.",Chronic Myelogenous Leukemia,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.gleevec:2,hc,Health Canada approved imatinib mesylate ,GLEEVEC (imatinib mesylate) is indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.gleevec:3,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['BCR::ABL1 [present]']
ind:hc.gleevec:4,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myelodysplastic Syndromes,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRA rearrangements [present]']
ind:hc.gleevec:4,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myelodysplastic Syndromes,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRB rearrangements [present]']
ind:hc.gleevec:4,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myeloproliferative Neoplasm,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRA rearrangements [present]']
ind:hc.gleevec:4,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,Myeloproliferative Neoplasm,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['PDGFRB rearrangements [present]']
ind:hc.gleevec:5,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.,Aggressive Systemic Mastocytosis,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['KIT p.D816V []']
ind:hc.gleevec:6,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.,"Chronic Eosinophilic Leukemia, NOS",https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['FIP1L1::PDGFRA [present]']
ind:hc.gleevec:7,hc,Health Canada approved imatinib mesylate for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,Gastrointestinal Stromal Tumor,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:hc.gleevec:8,hc,Health Canada approved imatinib mesylate for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.,GLEEVEC (imatinib mesylate) is indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.,Gastrointestinal Stromal Tumor,https://pdf.hres.ca/dpd_pm/00067276.PDF,2021-08-31,['Imatinib'],Monotherapy,['Bcr-Abl inhibition'],['Targeted therapy'],['CD117 + [present]']
ind:hc.herceptin:0,hc,"Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.","HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080472.PDF,2025-05-02,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.herceptin:1,hc,"Health Canada approved trastuzumab in combination with paclitaxel or docetaxel for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide.","HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080472.PDF,2025-05-02,"['Paclitaxel', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Taxane-based chemotherapy', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.herceptin:2,hc,"Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.","HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080472.PDF,2025-05-02,"['Carboplatin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.herceptin:3,hc,Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.,HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.,Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080472.PDF,2025-05-02,['Trastuzumab'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.herceptin:4,hc,Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,HERCEPTIN (trastuzumab for injection) can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080472.PDF,2025-05-02,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.ibrance:0,hc,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hc.ibrance:0,hc,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hc.ibrance:0,hc,"Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Letrozole', 'Palbociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:hc.ibrance:1,hc,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hc.ibrance:1,hc,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hc.ibrance:1,hc,"Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.","IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080011.PDF,2025-03-24,"['Fulvestrant', 'Palbociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:hc.iclusig:0,hc,"Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.","ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance",Chronic Myelogenous Leukemia,https://pdf.hres.ca/dpd_pm/00078669.PDF,2025-02-24,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],['ABL1 p.T315I [present]']
ind:hc.iclusig:1,hc,"Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.","ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including Ph+ ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance",Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00078669.PDF,2025-02-24,['Ponatinib'],Monotherapy,['BCR-ABL inhibition'],['Targeted therapy'],"['BCR::ABL1 [present]', 'ABL1 p.T315I [present]']"
ind:hc.imfinzi:0,hc,Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080178.PDF,2025-04-10,"['Tremelimumab', 'Durvalumab', 'Carboplatin']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Immunotherapy', 'Chemotherapy']","['Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hc.imfinzi:1,hc,"Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.","Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.",Endometrial Carcinoma,https://pdf.hres.ca/dpd_pm/00080178.PDF,2025-04-10,"['Durvalumab', 'Paclitaxel', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['dMMR [present]']
ind:hc.iressa:0,hc,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00060650.PDF,2021-03-31,['Gefitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:hc.iressa:0,hc,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00060650.PDF,2021-03-31,['Gefitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:hc.iressa:0,hc,Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ,IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00060650.PDF,2021-03-31,['Gefitinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR oncogenic variants [present]']
ind:hc.itovebi:0,hc,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078611.PDF,2025-02-14,"['Palbociclib', 'Inavolisib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'PIK3CA somatic variants [present]']"
ind:hc.itovebi:0,hc,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078611.PDF,2025-02-14,"['Palbociclib', 'Inavolisib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]', 'PIK3CA somatic variants [present]']"
ind:hc.itovebi:0,hc,"Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.","ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078611.PDF,2025-02-14,"['Palbociclib', 'Inavolisib', 'Fulvestrant']",Combination Therapy,"['CDK4/6 inhibition', 'PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]', 'PIK3CA somatic variants [present]']"
ind:hc.jemperli:0,hc,Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,Endometrial Carcinoma,https://pdf.hres.ca/dpd_pm/00080289.PDF,2025-04-16,['Dostarlimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:hc.jemperli:0,hc,Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.,Endometrial Carcinoma,https://pdf.hres.ca/dpd_pm/00080289.PDF,2025-04-16,['Dostarlimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:hc.kadcyla:0,hc,"Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.","KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00067729.PDF,2022-10-13,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.kadcyla:1,hc,Health Canada approved trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.,KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.,Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00067729.PDF,2022-10-13,['Trastuzumab emtansine'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],['HER2-positive [present]']
ind:hc.keytruda:0,hc,"Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.","KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",Melanoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['BRAF p.V600E [present]']
ind:hc.keytruda:0,hc,"Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.","KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.",Melanoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['BRAF p.V600K [present]']
ind:hc.keytruda:1,hc,"Health Canada approved pembrolizumab for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS) ≥ 1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.","KEYTRUDA (pembrolizumab) as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS) ≥ 1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 1% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hc.keytruda:3,hc,Health Canada approved pembrolizumab as a monotherapy for treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS ≥ 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.,KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS ≥ 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 1% [present]']
ind:hc.keytruda:4,hc,Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.,"KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:hc.keytruda:4,hc,Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.,"KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.",Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:hc.keytruda:5,hc,,"KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",Any solid tumor,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['dMMR [present]']
ind:hc.keytruda:5,hc,,"KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",Any solid tumor,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['MSI-H [present]']
ind:hc.keytruda:7,hc,"Health Canada approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS] ≥ 1) as determined by a validated test.","KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS] ≥ 1) as determined by a validated test.",Head and Neck Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,['Pembrolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 (CPS) >= 1 [present]']
ind:hc.keytruda:8,hc,"Health Canada approved pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by a validated test.",Adenocarcinoma of the Gastroesophageal Junction,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Pembrolizumab', 'Cisplatin', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Platinum-based chemotherapy', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']","['HER2-positive [present]', 'PD-L1 (CPS) >= 1 [present]']"
ind:hc.keytruda:9,hc,"Health Canada approved pembrolizumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.","KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",Adenocarcinoma of the Gastroesophageal Junction,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['HER2-negative [present]']
ind:hc.keytruda:10,hc,"Health Canada approved pembrolizumab, in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 10) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 10) as determined by a validated test.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Paclitaxel', 'Pembrolizumab']",Combination Therapy,"['Taxane-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Immunotherapy']","['PR negative [present]', 'HER2-negative [present]', 'PD-L1 (CPS) >= 10 [present]', 'ER negative [present]']"
ind:hc.keytruda:11,hc,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.",Cervical Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Pembrolizumab', 'Bevacizumab', 'Paclitaxel', 'Cisplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'VEGF inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']","['Immunotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hc.keytruda:11,hc,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.",Cervical Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Pembrolizumab', 'Bevacizumab', 'Paclitaxel', 'Cisplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'VEGF inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy']","['Immunotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hc.keytruda:11,hc,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.",Cervical Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Pembrolizumab', 'Paclitaxel', 'Bevacizumab', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'VEGF inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hc.keytruda:11,hc,"Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.","KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.",Cervical Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00080285.PDF,2025-04-11,"['Pembrolizumab', 'Paclitaxel', 'Bevacizumab', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy', 'VEGF inhibition', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['PD-L1 (CPS) >= 1 [present]']
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Anastrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Anastrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Anastrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hc.kisqali:0,hc,"Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.","KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Letrozole', 'Ribociclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hc.kisqali:1,hc,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hc.kisqali:1,hc,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hc.kisqali:1,hc,"Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.","KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00075798.PDF,2024-05-31,"['Fulvestrant', 'Ribociclib']",Combination Therapy,"['Estrogen receptor inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:hc.lazcluze:0,hc,Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078792.PDF,2025-03-06,"['Lazertinib', 'Amivantamab']",Combination Therapy,"['EGFR inhibition', 'EGFR inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR Exon 19 (Deletion) [present]']
ind:hc.lazcluze:0,hc,Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078792.PDF,2025-03-06,"['Lazertinib', 'Amivantamab']",Combination Therapy,"['EGFR inhibition', 'EGFR inhibition']","['Targeted therapy', 'Targeted therapy']",['EGFR p.L858R [present]']
ind:hc.libtayo:0,hc,"Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.","LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078455.PDF,2025-01-30,['Cemiplimab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ROS1 [present]', 'Wild type EGFR [present]', 'Wild type ALK [present]', 'PD-L1 >= 50% [present]']"
ind:hc.libtayo:0,hc,"Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.","LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078455.PDF,2025-01-30,"['Cemiplimab', 'Pemetrexed', 'Carboplatin']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy']","['Wild type EGFR [present]', 'Wild type ROS1 [present]', 'Wild type ALK [present]']"
ind:hc.lorbrena:0,hc,Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00077541.PDF,2024-10-28,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.lorbrena:1,hc,"Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.","LORBRENA (lorlatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00077541.PDF,2024-10-28,['Lorlatinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.lumakras:0,hc,Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.,LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078781.PDF,2025-03-04,['Sotorasib'],Monotherapy,['RAS inhibition'],['Targeted therapy'],['KRAS p.G12C [present]']
ind:hc.lynparza:0,hc,"Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.","LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'BRCA1 pathogenic variants [present]']"
ind:hc.lynparza:0,hc,"Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.","LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:hc.lynparza:1,hc,"Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.","LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'BRCA1 pathogenic variants [present]']"
ind:hc.lynparza:1,hc,"Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.","LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],"['BRCA2 pathogenic variants [present]', 'HER2-negative [present]']"
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:2,hc,"Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy.","LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Ovarian Epithelial Tumor,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",High-Grade Serous Fallopian Tube Cancer,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:3,hc,"Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.","LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.",Peritoneal Serous Carcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Bevacizumab', 'Olaparib']",Combination Therapy,"['VEGF inhibition', 'PARP inhibition']","['Targeted therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:4,hc,Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.,LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Pancreatic Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:4,hc,Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.,LYNPARZA (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Pancreatic Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['ATM pathogenic variants [present]']
ind:hc.lynparza:5,hc,Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent.,LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,['Olaparib'],Monotherapy,['PARP inhibition'],['Targeted therapy'],['ATM oncogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Abiraterone acetate', 'Prednisolone', 'Olaparib']",Combination Therapy,"['Antiandrogen', 'Corticosteroid', 'PARP inhibition']","['Hormone therapy', 'Chemotherapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Abiraterone acetate', 'Prednisolone', 'Olaparib']",Combination Therapy,"['Antiandrogen', 'Corticosteroid', 'PARP inhibition']","['Hormone therapy', 'Chemotherapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Abiraterone acetate', 'Prednisolone', 'Olaparib']",Combination Therapy,"['Antiandrogen', 'Corticosteroid', 'PARP inhibition']","['Hormone therapy', 'Chemotherapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Abiraterone acetate', 'Prednisolone', 'Olaparib']",Combination Therapy,"['Antiandrogen', 'Corticosteroid', 'PARP inhibition']","['Hormone therapy', 'Chemotherapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Prednisone', 'Abiraterone acetate', 'Olaparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 oncogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Prednisone', 'Abiraterone acetate', 'Olaparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA1 pathogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Prednisone', 'Abiraterone acetate', 'Olaparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA2 oncogenic variants [present]']
ind:hc.lynparza:6,hc,Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.,LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.,Prostate Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00080379.PDF,2025-04-29,"['Prednisone', 'Abiraterone acetate', 'Olaparib']",Combination Therapy,"['Corticosteroid', 'Antiandrogen', 'PARP inhibition']","['Chemotherapy', 'Hormone therapy', 'Targeted therapy']",['BRCA2 pathogenic variants [present]']
ind:hc.mekinist:0,hc,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.","MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",Melanoma,https://pdf.hres.ca/dpd_pm/00077955.PDF,2024-12-05,['Trametinib'],Monotherapy,['MEK inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:hc.mekinist:0,hc,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.","MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",Melanoma,https://pdf.hres.ca/dpd_pm/00077955.PDF,2024-12-05,['Trametinib'],Monotherapy,['MEK inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:hc.mekinist:2,hc,Health Canada approved trametinib in combination with dabrafenib for the treatment of patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).,MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00077955.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.mekinist:3,hc,Health Canada approved trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with BRAF V600E-mutant low-grade glioma (LGG) requiring systemic therapy.,MEKINIST (trametinib) in combination with dabrafenib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,"Low-Grade Glioma, NOS",https://pdf.hres.ca/dpd_pm/00077955.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.mekinist:0,hc,"Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.","MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.","High-Grade Glioma, NOS",https://pdf.hres.ca/dpd_pm/00077955.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.mektovi:0,hc,"Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.","MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",Melanoma,https://pdf.hres.ca/dpd_pm/00060288.PDF,2021-03-02,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.mektovi:0,hc,"Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.","MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.",Melanoma,https://pdf.hres.ca/dpd_pm/00060288.PDF,2021-03-02,"['Binimetinib', 'Encorafenib']",Combination Therapy,"['MEK inhibition', 'B-RAF inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600K [present]']
ind:hc.mylotarg:0,hc,"Health Canada approved gemtuzumab ozogamicin  in combination with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.","Mylotarg (gemtuzumab ozogamicin for injection) is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.",Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00069427.PDF,2023-02-02,"['Daunorubicin', 'Cytarabine', 'Gemtuzumab ozogamicin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'CD33 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD33 + [present]']
ind:hc.nerlynx:0,hc,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00062158.PDF,2021-07-16,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hc.nerlynx:0,hc,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00062158.PDF,2021-07-16,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['HER2-positive [present]', 'ER positive [present]']"
ind:hc.nerlynx:0,hc,"Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.","NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00062158.PDF,2021-07-16,['Neratinib'],Monotherapy,['HER2 inhibition'],['Targeted therapy'],"['PR positive [present]', 'HER2-positive [present]']"
ind:hc.nerlynx:1,hc,"Health Canada approved neratinib in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.","NERLYNX (neratinib) is indicated in combination with capecitabine for the treatment of patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00062158.PDF,2021-07-16,"['Neratinib', 'Capecitabine']",Combination Therapy,"['HER2 inhibition', 'Thymidylate synthase inhibition']","['Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.opdivo:0,hc,"Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.","OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",Melanoma,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,['Nivolumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['BRAF p.V600E [present]']
ind:hc.opdivo:0,hc,"Health Canada approved nivolumab for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.","OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.",Melanoma,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,['Nivolumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['BRAF p.V600K [present]']
ind:hc.opdivo:2,hc,"Health Canada approved nivolumab in combination with ipilimumab, for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.","OPDIVO (nivolumab) in combination with ipilimumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'PD-L1 >= 1% [present]', 'Wild type ALK [present]']"
ind:hc.opdivo:6,hc,"Health Canada approved nivolumab, in combination with ipilimuab, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.","OPDIVO (nivolumab), in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",Esophageal Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hc.opdivo:7,hc,"Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.","OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",Esophageal Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,"['Fluorouracil', 'Cisplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hc.opdivo:7,hc,"Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.","OPDIVO (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",Esophageal Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00076152.PDF,2024-06-28,"['Fluorouracil', 'Oxaliplatin', 'Nivolumab']",Combination Therapy,"['Thymidylate synthase inhibition', 'Platinum-based chemotherapy', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hc.pemazyre:0,hc,"Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.","PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00062968.PDF,2021-09-08,['Pemigatinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2::v [present]']
ind:hc.pemazyre:0,hc,"Health Canada approved pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.","PEMAZYRE (pemigatinib) is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.",Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00062968.PDF,2021-09-08,['Pemigatinib'],Monotherapy,['FGFR inhibition'],['Targeted therapy'],['FGFR2 rearrangements [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Paclitaxel', 'Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Paclitaxel', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Cyclophosphamide', 'Pertuzumab', 'Doxorubicin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Carboplatin', 'Trastuzumab', 'Paclitaxel', 'Pertuzumab']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.perjeta:0,hc,"Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PERJETA (pertuzumab for injection) in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Pertuzumab', 'Trastuzumab', 'Vinorelbine']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition', 'Vinca alkaloid chemotherapy']","['Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.perjeta:1,hc,Health Canada approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,PERJETA (pertuzumab) is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00060125.PDF,2013-04-12,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab', 'Doxorubicin']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Paclitaxel', 'Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Fluorouracil']",Combination Therapy,"['Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Pertuzumab', 'Trastuzumab', 'Paclitaxel', 'Doxorubicin', 'Fluorouracil']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'Topoisomerase inhibition', 'Thymidylate synthase inhibition']","['Chemotherapy', 'Targeted therapy', 'Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Epirubicin', 'Cyclophosphamide', 'Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['Topoisomerase inhibition', 'Alkylating chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Epirubicin', 'Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Cyclophosphamide', 'Pertuzumab', 'Doxorubicin', 'Trastuzumab', 'Docetaxel']",Combination Therapy,"['Alkylating chemotherapy', 'HER2 inhibition', 'Topoisomerase inhibition', 'HER2 inhibition', 'Taxane-based chemotherapy']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Pertuzumab', 'Docetaxel', 'Carboplatin', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'Platinum-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Carboplatin', 'Trastuzumab', 'Paclitaxel', 'Pertuzumab']",Combination Therapy,"['Platinum-based chemotherapy', 'HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Pertuzumab', 'Paclitaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.phesgo:0,hc,"Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.","PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Pertuzumab', 'Trastuzumab', 'Vinorelbine']",Combination Therapy,"['HER2 inhibition', 'HER2 inhibition', 'Vinca alkaloid chemotherapy']","['Targeted therapy', 'Targeted therapy', 'Chemotherapy']",['HER2-positive [present]']
ind:hc.phesgo:2,hc,"Health Canada approved pertuzumab and trastuzumab in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anit-HER2 therapy or chemotherapy for metastatic disease.","PHESGO (pertuzumab and trastuzumab), is indicated in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064237.PDF,2022-01-05,"['Pertuzumab', 'Docetaxel', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Taxane-based chemotherapy', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.retevmo:0,hc,Health Canada approved selpercatinib as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078253.PDF,2025-01-10,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:hc.retevmo:1,hc,Health Canada approved selpercatinib as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.,Medullary Thyroid Cancer,https://pdf.hres.ca/dpd_pm/00078253.PDF,2025-01-10,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['RET oncogenic variants [present]']
ind:hc.retevmo:2,hc,Health Canada approved selpercatinib as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.,RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.,Papillary Thyroid Cancer,https://pdf.hres.ca/dpd_pm/00078253.PDF,2025-01-10,['Selpercatinib'],Monotherapy,['RET inhibition'],['Targeted therapy'],['v::RET [present]']
ind:hc.revlimid:0,hc,Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.,REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.,Myelodysplastic Syndromes,https://pdf.hres.ca/dpd_pm/00074535.PDF,2024-02-09,['Lenalidomide'],Monotherapy,['Angiogenesis inhibition'],['Chemotherapy'],['5q deletion [present]']
ind:hc.rituxan:0,hc,"Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.","RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.",Non-Hodgkin Lymphoma,https://pdf.hres.ca/dpd_pm/00071131.PDF,2023-06-02,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hc.rituxan:0,hc,"Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.","RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma.",Follicular Lymphoma,https://pdf.hres.ca/dpd_pm/00071131.PDF,2023-06-02,['Rituximab'],Monotherapy,['CD20 inhibition'],['Immunotherapy'],['CD20 + [present]']
ind:hc.rituxan:1,hc,"Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP chemotherapy.","RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.",Diffuse Large B-Cell Lymphoma,https://pdf.hres.ca/dpd_pm/00071131.PDF,2023-06-02,"['Cyclophosphamide', 'Doxorubicin', 'Rituximab', 'Prednisone', 'Vincristine']",Combination Therapy,"['Alkylating chemotherapy', 'Topoisomerase inhibition', 'CD20 inhibition', 'Corticosteroid', 'Vinca alkaloid chemotherapy']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hc.rituxan:1,hc,"Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP chemotherapy.","RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.",Diffuse Large B-Cell Lymphoma,https://pdf.hres.ca/dpd_pm/00071131.PDF,2023-06-02,"['Doxorubicin', 'Vincristine', 'Cyclophosphamide', 'Prednisolone', 'Rituximab']",Combination Therapy,"['Topoisomerase inhibition', 'Vinca alkaloid chemotherapy', 'Alkylating chemotherapy', 'Corticosteroid', 'CD20 inhibition']","['Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy', 'Immunotherapy']",['CD20 + [present]']
ind:hc.rituxan:2,hc,"Health Canada approved rituximab for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy.","RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy.",Follicular Lymphoma,https://pdf.hres.ca/dpd_pm/00071131.PDF,2023-06-02,"['Rituximab', 'Cyclophosphamide', 'Vincristine', 'Prednisolone']",Combination Therapy,"['CD20 inhibition', 'Alkylating chemotherapy', 'Vinca alkaloid chemotherapy', 'Corticosteroid']","['Immunotherapy', 'Chemotherapy', 'Chemotherapy', 'Chemotherapy']",['CD20 + [present]']
ind:hc.rozlytrek:0,hc,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.","ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",Any solid tumor,https://pdf.hres.ca/dpd_pm/00073345.PDF,2023-11-09,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:hc.rozlytrek:0,hc,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.","ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",Any solid tumor,https://pdf.hres.ca/dpd_pm/00073345.PDF,2023-11-09,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:hc.rozlytrek:0,hc,"Health Canada approved entrectinib for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.","ROZLYTREK (entrectinib) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options.",Any solid tumor,https://pdf.hres.ca/dpd_pm/00073345.PDF,2023-11-09,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:hc.rozlytrek:1,hc,Health Canada approved entrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.,ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00073345.PDF,2023-11-09,['Entrectinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:hc.rybrevant:0,hc,"Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.","RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078295.PDF,2025-01-13,"['Pemetrexed', 'Carboplatin', 'Amivantamab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR Exon 19 (Deletion) [present]']
ind:hc.rybrevant:0,hc,"Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.","RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078295.PDF,2025-01-13,"['Pemetrexed', 'Carboplatin', 'Amivantamab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR p.L858R [present]']
ind:hc.rybrevant:1,hc,Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.,RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078295.PDF,2025-01-13,"['Pemetrexed', 'Carboplatin', 'Amivantamab']",Combination Therapy,"['Antifolate', 'Platinum-based chemotherapy', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR Exon 20 (Insertion) [present]']
ind:hc.rybrevant:2,hc,Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.,RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078295.PDF,2025-01-13,['Amivantamab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 20 (Insertion) [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3-ITD [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835Y [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835A [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835E [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835H [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835N [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835S [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.D835V [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Cytarabine', 'Daunorubicin', 'Midostaurin']",Combination Therapy,"['DNA Polymerase inhibition', 'DNA Polymerase inhibition', 'FLT3 inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['FLT3 p.I836del [present]']
ind:hc.rydapt:0,hc,Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00070168.PDF,2023-03-31,"['Midostaurin', 'Cytarabine', 'Daunorubicin']",Combination Therapy,"['FLT3 inhibition', 'DNA Polymerase inhibition', 'DNA Polymerase inhibition']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['FLT3-ITD [present]']
ind:hc.tabrecta:0,hc,Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00071417.PDF,2023-06-26,['Capmatinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Splice Site) [present]']
ind:hc.tabrecta:0,hc,Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00071417.PDF,2023-06-26,['Capmatinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Deletion) [present]']
ind:hc.tafinlar:0,hc,"Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.","TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",Melanoma,https://pdf.hres.ca/dpd_pm/00077956.PDF,2024-12-05,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:hc.tafinlar:0,hc,"Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.","TAFINLAR (dabrafenib mesylate) is indicated as a monotherapy, or in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",Melanoma,https://pdf.hres.ca/dpd_pm/00077956.PDF,2024-12-05,['Dabrafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:hc.tafinlar:2,hc,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00077956.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.tafinlar:3,hc,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,"Low-Grade Glioma, NOS",https://pdf.hres.ca/dpd_pm/00077956.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.tafinlar:4,hc,Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.,TAFINLAR (dabrafenib mesylate) in combination with trametinib is indicated for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.,"High-Grade Glioma, NOS",https://pdf.hres.ca/dpd_pm/00077956.PDF,2024-12-05,"['Dabrafenib', 'Trametinib']",Combination Therapy,"['B-RAF inhibition', 'MEK inhibition']","['Targeted therapy', 'Targeted therapy']",['BRAF p.V600E [present]']
ind:hc.tagrisso:0,hc,Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:hc.tagrisso:0,hc,Health Canada approved osimertinib as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA1 non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:hc.tagrisso:1,hc,"Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.","TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:hc.tagrisso:1,hc,"Health Canada approved osimertinib for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during opr following platinum based chemoradiation therapy.","TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum based chemoradiation therapy.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:hc.tagrisso:2,hc,"Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.","TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR Exon 19 (Deletion) [present]']
ind:hc.tagrisso:2,hc,"Health Canada approved osimertinib for the first-line  treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.","TAGRISSO (osimertinib) is indicated for the first-line treatment of patients with locally advanced (not amenable to curative therapies), or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.L858R [present]']
ind:hc.tagrisso:3,hc,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,"['Osimertinib', 'Pemetrexed', 'Cisplatin']",Combination Therapy,"['EGFR inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['EGFR p.L858R [present]']
ind:hc.tagrisso:3,hc,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,"['Carboplatin', 'Pemetrexed', 'Osimertinib']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR p.L858R [present]']
ind:hc.tagrisso:3,hc,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,"['Carboplatin', 'Pemetrexed', 'Osimertinib']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'EGFR inhibition']","['Chemotherapy', 'Chemotherapy', 'Targeted therapy']",['EGFR Exon 19 (Deletion) [present]']
ind:hc.tagrisso:3,hc,Health Canada approved osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,TAGRISSO (osimertinib) is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,"['Osimertinib', 'Pemetrexed', 'Cisplatin']",Combination Therapy,"['EGFR inhibition', 'Antifolate', 'Platinum-based chemotherapy']","['Targeted therapy', 'Chemotherapy', 'Chemotherapy']",['EGFR Exon 19 (Deletion) [present]']
ind:hc.tagrisso:4,hc,Health Canada approved osimertinib for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.,TAGRISSO (osimertinib) is indicated for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00080336.PDF,2025-04-23,['Osimertinib'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],['EGFR p.T790M [present]']
ind:hc.tecentriq:0,hc,Health Canada approved,"TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with Stage II to IIIA* NSCLC whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs)",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078266.PDF,2025-01-09,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],['PD-L1 >= 50% [present]']
ind:hc.tecentriq:1,hc,"Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078266.PDF,2025-01-09,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['PD-L1 >= 50% [present]', 'Wild type ALK [present]', 'Wild type EGFR [present]']"
ind:hc.tecentriq:1,hc,"Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.","TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained ≥ 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering ≥ 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00078266.PDF,2025-01-09,['Atezolizumab'],Monotherapy,['PD-1/PD-L1 inhibition'],['Immunotherapy'],"['Wild type ALK [present]', 'PD-L1 >= 10% TIIC [present]', 'Wild type EGFR [present]']"
ind:hc.tecentriq:5,hc,"Health Canada approved atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering ≥ 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.","TECENTRIQ (atezolizumab) in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression on tumour-infiltrating immune cells (IC) covering ≥ 1% of the tumour area, and who have not received prior chemotherapy for metastatic disease.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078266.PDF,2025-01-09,"['Atezolizumab', 'Nab-paclitaxel']",Combination Therapy,"['PD-1/PD-L1 inhibition', 'Taxane-based chemotherapy']","['Immunotherapy', 'Chemotherapy']","['PD-L1 >= 1% [present]', 'ER negative [present]', 'PR negative [present]', 'HER2-negative [present]']"
ind:hc.tepmetko:0,hc,Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00074821.PDF,2024-03-04,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Splice Site) [present]']
ind:hc.tepmetko:0,hc,Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,TEPMETKO (tepotinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00074821.PDF,2024-03-04,['Tepotinib'],Monotherapy,['MET inhibition'],['Targeted therapy'],['MET Exon 14 (Deletion) [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132C [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132G [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132H [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132L [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,"['Azacitidine', 'Ivosidenib']",Combination Therapy,"['Hypomethylating agent chemotherapy', 'IDH1 inhibition']","['Chemotherapy', 'Targeted therapy']",['IDH1 p.R132S [present]']
ind:hc.tibsovo:1,hc,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132C [present]']
ind:hc.tibsovo:1,hc,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132G [present]']
ind:hc.tibsovo:1,hc,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132H [present]']
ind:hc.tibsovo:1,hc,Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.,Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132L [present]']
ind:hc.tibsovo:0,hc,Health Canada approved ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,TIBSOVO (ivosidenib) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy.,Cholangiocarcinoma,https://pdf.hres.ca/dpd_pm/00076398.PDF,2024-07-19,['Ivosidenib'],Monotherapy,['IDH1 inhibition'],['Targeted therapy'],['IDH1 p.R132S [present]']
ind:hc.trodelvy:0,hc,"Health Canada approved sacituzumab govitecan for the treatment of adult  patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080546.PDF,2025-05-14,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['ER positive [present]', 'HER2-negative [present]']"
ind:hc.trodelvy:0,hc,"Health Canada approved sacituzumab govitecan for the treatment of adult  patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","TRODELVY (sacituzumab govitecan) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00080546.PDF,2025-05-14,['Sacituzumab govitecan'],Monotherapy,['Topoisomerase inhibition'],['Targeted therapy'],"['PR positive [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'PIK3CA somatic variants [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PIK3CA somatic variants [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'AKT1 somatic variants [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'HER2-negative [present]', 'AKT1 somatic variants [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'HER2-negative [present]', 'AKT1 somatic variants [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'HER2-negative [present]', 'AKT1 amplification [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]', 'AKT1 amplification [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['AKT1 amplification [present]', 'HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN nonsense variants [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN nonsense variants [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PTEN nonsense variants [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PTEN frameshift variants [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN frameshift variants [present]', 'HER2-negative [present]', 'PR positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'ER positive [present]', 'PTEN frameshift variants [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN splice site variants [present]', 'ER positive [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN splice site variants [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PTEN splice site variants [present]', 'PR positive [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PTEN deletion [present]', 'ER positive [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PR positive [present]', 'PTEN deletion [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['ER positive [present]', 'PTEN deletion [present]', 'PR positive [present]', 'HER2-negative [present]']"
ind:hc.truqap:0,hc,"Health Canada approved capivasertib, in combination with fulvestrant, for the  treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.","TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00078178.PDF,2025-01-03,"['Capivasertib', 'Fulvestrant']",Combination Therapy,"['PI3K/AKT/mTOR inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['PIK3CA amplification [present]', 'HER2-negative [present]', 'ER positive [present]']"
ind:hc.tukysa:0,hc,"Health Canada approved tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.","TUKYSA (tucatinib) is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00062119.PDF,2021-07-08,"['Tucatinib', 'Capecitabine', 'Trastuzumab']",Combination Therapy,"['HER2 inhibition', 'Thymidylate synthase inhibition', 'HER2 inhibition']","['Targeted therapy', 'Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.tykerb:0,hc,"Health Canada approved lapatinib in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.","TYKERB (lapatinib tablets) is indicated for in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00064944.PDF,2022-03-02,"['Capecitabine', 'Lapatinib']",Combination Therapy,"['Thymidylate synthase inhibition', 'HER2 inhibition']","['Chemotherapy', 'Targeted therapy']",['HER2-positive [present]']
ind:hc.vectibix:1,hc,"Health Canada approved panitumumab as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.","VECTIBIX (panitumumab for injection) is indicated as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",Colorectal Adenocarcinoma,https://pdf.hres.ca/dpd_pm/00063326.PDF,2021-10-25,['Panitumumab'],Monotherapy,['EGFR inhibition'],['Targeted therapy'],"['Wild type KRAS [present]', 'Wild type NRAS [present]']"
ind:hc.verzenio:0,hc,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]']"
ind:hc.verzenio:0,hc,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'PR positive [present]']"
ind:hc.verzenio:0,hc,"Health Canada approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.","VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Abemaciclib', 'Tamoxifen']",Combination Therapy,"['CDK4/6 inhibition', 'Estrogen receptor inhibition']","['Targeted therapy', 'Hormone therapy']","['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['HER2-negative [present]', 'PR positive [present]', 'ER positive [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['ER positive [present]', 'HER2-negative [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,"['Exemestane', 'Abemaciclib']",Combination Therapy,"['Aromatase inhibition', 'CDK4/6 inhibition']","['Hormone therapy', 'Targeted therapy']","['PR positive [present]', 'HER2-negative [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,['Abemaciclib'],Monotherapy,['CDK4/6 inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'ER positive [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,['Abemaciclib'],Monotherapy,['CDK4/6 inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'PR positive [present]']"
ind:hc.verzenio:1,hc,"Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.","VERZENIO (abemaciclib) is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy, in combination with fulvestrant in women with disease progression following endocrine therapy, or as a single agent in women with disease progression following endocrine therapy and at least 2 prior chemotherapy regimens.",Invasive Breast Carcinoma,https://pdf.hres.ca/dpd_pm/00073683.PDF,2023-12-01,['Abemaciclib'],Monotherapy,['CDK4/6 inhibition'],['Targeted therapy'],"['HER2-negative [present]', 'ER positive [present]', 'PR positive [present]']"
ind:hc.vitrakvi:0,hc,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,Any solid tumor,https://pdf.hres.ca/dpd_pm/00076917.PDF,2024-09-03,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK1 [present]']
ind:hc.vitrakvi:0,hc,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,Any solid tumor,https://pdf.hres.ca/dpd_pm/00076917.PDF,2024-09-03,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK2 [present]']
ind:hc.vitrakvi:0,hc,Health Canada approved larotrectinib for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation.,Any solid tumor,https://pdf.hres.ca/dpd_pm/00076917.PDF,2024-09-03,['Larotrectinib'],Monotherapy,['NTRK inhibition'],['Targeted therapy'],['v::NTRK3 [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132C [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132G [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132H [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132L [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132S [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172K [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172M [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172G [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172S [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Astrocytoma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172W [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132C [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132G [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132H [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132L [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH1 p.R132S [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172K [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172M [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172G [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172S [present]']
ind:hc.voranigo:0,hc,Health Canada approved vorasidenib for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,VORANIGO (vorasidenib tablets) is indicated for the treatment of Grade 2a astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention.,Oligodendroglioma,https://pdf.hres.ca/dpd_pm/00076841.PDF,2024-08-27,['Vorasidenib'],Monotherapy,['IDH1/2 inhibition'],['Targeted therapy'],['IDH2 p.R172W [present]']
ind:hc.vyloy:0,hc,"Health Canada approved zolbetuximab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.","Vyloy (zolbetuximab for injection), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive as determined by a validated test.",Adenocarcinoma of the Gastroesophageal Junction,https://pdf.hres.ca/dpd_pm/00078035.PDF,2024-12-13,"['Oxaliplatin', 'Capecitabine', 'Zolbetuximab']",Combination Therapy,"['Platinum-based chemotherapy', 'Thymidylate synthase inhibition', 'CLDN18.2 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy']","['HER2-negative [present]', 'CLDN18.2 >= 75% [present]']"
ind:hc.xalkori:0,hc,Health Canada approved crizotinib for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,XALKORI (crizotinib) is indicated for use as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00070448.PDF,2023-04-17,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.xalkori:1,hc,Health Canada approved crizotinib for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,XALKORI (crizotinib) is indicated for use in patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00070448.PDF,2023-04-17,['Crizotinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ROS1 [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3-ITD [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Myeloid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835Y [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835A [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835E [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835H [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835N [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835S [present]']
ind:hc.xospata:0,hc,Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.,XOSPATA (gilteritinib tablets) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.,Acute Lymphoid Leukemia,https://pdf.hres.ca/dpd_pm/00064190.PDF,2022-01-04,['Gilteritinib'],Monotherapy,['FLT3 inhibition'],['Targeted therapy'],['FLT3 p.D835V [present]']
ind:hc.yervoy:0,hc,"Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.","YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with metastatic NSCLC, expressing PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00074279.PDF,2023-12-07,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'PD-L1 >= 1% [present]', 'Wild type ALK [present]']"
ind:hc.yervoy:1,hc,"Health Canada approved ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.","YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC.",Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00074279.PDF,2023-12-07,"['Cisplatin', 'Pemetrexed', 'Ipilimumab', 'Nivolumab']",Combination Therapy,"['Platinum-based chemotherapy', 'Antifolate', 'CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Chemotherapy', 'Chemotherapy', 'Immunotherapy', 'Immunotherapy']","['Wild type EGFR [present]', 'Wild type ALK [present]']"
ind:hc.yervoy:3,hc,"Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.","YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression ≥ 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.",Esophageal Squamous Cell Carcinoma,https://pdf.hres.ca/dpd_pm/00074279.PDF,2023-12-07,"['Ipilimumab', 'Nivolumab']",Combination Therapy,"['CTLA-4 inhibition', 'PD-1/PD-L1 inhibition']","['Immunotherapy', 'Immunotherapy']",['PD-L1 >= 1% [present]']
ind:hc.zelboraf:0,hc,Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,ZELBORAF (vemurafenib) is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,Melanoma,https://pdf.hres.ca/dpd_pm/00054278.PDF,2019-12-10,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600E [present]']
ind:hc.zelboraf:0,hc,Health Canada approved vemurafenib as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,ZELBORAF (vemurafenib) is indicated as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. A validated test is required to identify BRAF V600 mutation status.,Melanoma,https://pdf.hres.ca/dpd_pm/00054278.PDF,2019-12-10,['Vemurafenib'],Monotherapy,['B-RAF inhibition'],['Targeted therapy'],['BRAF p.V600K [present]']
ind:hc.zykadia:0,hc,Health Canada approved ceritinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,ZYKADIA (ceritinib) as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00064867.PDF,2022-02-25,['Ceritinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
ind:hc.zykadia:1,hc,Health Canada approved ceritinib for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.,ZYKADIA (ceritinib) as monotherapy is indicated for the treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.,Non-Small Cell Lung Cancer,https://pdf.hres.ca/dpd_pm/00064867.PDF,2022-02-25,['Ceritinib'],Monotherapy,['ALK inhibition'],['Targeted therapy'],['v::ALK [present]']
